Childhood neuroblastoma is often a fatal disease. A new approach using a combination of two drugs shows promise in reducing ...

The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.

Adcendo, a biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that the U.S. Food & Drug Administration (FDA) has ...

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

"The goal is to expand treatment options for HER2-mutant NSCLC, which is currently a challenging and prognostically ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

在肿瘤研究的浩瀚征程中，科学家们从未停止探索的脚步。肿瘤的特征之一是不受控制的细胞分裂，并在此过程中伴随着DNA复制、细胞周期蛋白的表达和激活、微管蛋白重组等细胞活动。一些小分子抑制剂，例如DNA烷化和交联剂、CDK抑制剂等可以高效地阻断上述过程，进 ...

Introduction Antitumor antibiotics are a class of chemotherapy drugs derived from natural sources, primarily Streptomyces bacteria, and are wid ...

HONG KONG, China I7, 2025 I Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the ...